“Devices that are to be implanted in one’s body, whether it is a Class II or Class III Device should never be cleared to go to market under the 510K process. Surgical mesh, a Class II device has received clearance using this method, and thousands have been injured. I am merely one of these statistics.
“As a result of suffering these injuries, I began researching many surgical mesh devices cleared by the FDA. I have linked more than sixty of theses clearances, (as late as 2009) to Boston Scientific’s ProteGen Sling that was recalled by its own manufacturer in a letter to the FDA on January 22, 1999. The reason stated in the FDA’s March 17, 1999 Enforcement Report was “Use of the ProteGen in female urinary incontinence is associated with a higher than expected rate of vaginal erosion and dehiscence, and does not appear to function as intended.”
“These devices are all predicated upon one another, and even though the newer devices had not specifically used the recalled device as their predicate, I was able to link them through devices they used as predicates that were predicated by the ProteGen Sling. Following the FDA mesh clearance merry-go-round is not an easy task; it took me quite some time to master the research process of their website.
“One thing of interest I found was the clearance of the IN-SLING, manufactured by Influence Inc., and cleared by the FDA on September 19, 1997. The approval number is K972651. Within Influence Inc.’s document, under the subheading “Performance Standards” it was clearly stated “No performance standards applicable to surgical mesh have been established by the FDA” yet the FDA approved this device and has subsequently cleared many more surgical mesh devices over the last decade. If, as this document states, no performance standards had been established, neither this device nor its predecessor the ProteGen Sling should have received FDA clearance. Had these clearances not been issued, it would have saved thousands from being injured. The FDA is clearing these devices in a negligent and irresponsible manner predicated on greed.
“We must do away with the pharmaceutical lobbyist and get the pharmaceutical companies, the FDA, the doctors and our elected officials out of bed with each other. Until regulatory agencies in the United States can recognize and rectify these problems, we as a society are doomed to poor health care that’s cost is exorbitant; both in injuries and monetarily, and we as patients are paying the price.”